STOCKS TELEGRAPH

Tag: Motus GI Holdings

  • MOTUS GI (MOTS) Faces Pre-market Plunge Amidst Regulatory Woes

    Motus GI Holdings, Inc. (NASDAQ: MOTS) encountered a tumultuous trading session on Thursday, experiencing a notable 4% downturn. However, the real blow came after the closing bell, as the stock plummeted even further, shedding up to a staggering third of its value. As the early premarket hours of Friday unfolded, MOTS was found trading precariously at $0.29, marking a significant drop from its previous position.

    Low Trade Volume

    A concerning factor accompanying this decline is the strikingly low trading volume, hovering around 200,000 shares. This figure stands notably below the stock’s average trading volume, indicating minimal participation in the market. Such subdued activity hints at a limited number of players actively involved in exchanging shares, raising concerns about the depth of market interest in MOTS.

    The absence of any corroborating news behind this sharp decline adds to the apprehension among investors. With no substantial developments to justify the drastic price movement, many in the market fear the looming possibility of profit-taking activities in the coming days. Despite the prevailing uncertainty, bullish investors seem content to ride the wave for the time being, capitalizing on the current momentum.

    Nasdaq Delisting Concern

    Adding to MOTS’s woes is a recent notification letter from the Listing Qualifications Staff of Nasdaq. The letter highlighted the failure of the company’s common stock to maintain a bid price of at least $1 per share over the preceding 30 consecutive business days.

    Consequently, MOTS finds itself in non-compliance with Listing Rule 5550(a)(2). The communication further underscored the company’s ineligibility for any compliance period, citing previous reverse stock splits as contributing factors.

    This recent development compounds the challenges facing MOTS, exacerbating the uncertainties surrounding its stock performance.

    Investors are likely to monitor the company’s response to the Nasdaq notification closely, as it navigates through the intricacies of compliance requirements. Amidst the prevailing volatility and regulatory scrutiny, MOTS faces an uphill battle to restore investor confidence and stabilize its position in the market.

    Conclusion

    In conclusion, MOTS’s premarket price movement reflects a turbulent period for the company, characterized by significant declines and regulatory challenges. With minimal trading activity and no apparent catalysts driving the downturn, investors brace themselves for potential profit-taking pressures while closely monitoring the company’s compliance efforts.

  • Motus GI Holdings Inc. (MOTS) stock Rallies Premarket Following a Series of Stock Option Awards

    On February 11, 2022, Motus GI Holdings Inc. (MOTS) filed a series of Forms with the Securities Exchange Commission regarding certain option awards. Consequently, the stock rallied in the premarket on Monday.

    In the previous trading session, the stock remained in the red with a loss of 6.33% at $0.4250. Following the SEC filings of the company, MOTS rebounded in the premarket to gain a huge 57.65% at the last check. Hence, the stock was trading at $0.67 in the premarket, at the time of writing on Monday.

    The medical technology company, Motus GI Holdings Inc. is working on improving endoscopy outcomes and experiences. Currently, the company has a market capitalization of $20.52 million with 48.28 million shares outstanding. In the past five days, MOTS had added 8.95% while it has declined by 8.99% year to date. Furthermore, the stock subtracted a value of 75.43% last year.

    Recent Option Awards

    On Friday, the company registered as many as eight SEC filings regarding certain option awards. The option awards were granted to various members of the company including Morgan Timothy P., (Director & CEO), Mark Pomeranz (president, COO & director), and David P. Hochman (Chairman). MOTS’ independent directors, Nelson Sonja, Sherman Darren, Shervin Joe Korangy, and Gary J. Pruden were also granted option awards. Additionally, an officer of the company, Taylor Andrew Lawrence was also on the list of the names.

    These stock options were granted to the mentioned personnel of the company in accordance with its 2016 Equity Incentive Plan. Further details of the option awards are present on the company’s SEC filings page.

    MOTS Innovation Day

    On January 25, the company hosted an Innovation Day focusing on its Pure-Vu EVS System. The innovation day highlighted various aspects of the system including its commercial expansion and future product innovation. Moreover, the clinical initiatives for supporting reimbursement and market growth were also highlighted during the event.

    Pure-Vu EVS Systems, the third-gen Pure-Vu platform is designed for ease of use advancement. It offers enhanced physician navigation, control, on-demand bedside loading, expanded cleansing all with a much smaller workstation footprint. Presently, the system is under 510(k) review by the FDA.

    MOTS’ Financial Highlights

    In the third quarter of 2021, the company had a net loss of $4.8 million on revenue of $141,000. This compares to a net loss of $3.9 million on revenue of $33,000 in Q3 of 2020. Therefore, the net loss per basic and diluted share was $0.10 and $0.13 in the third quarter of 2021 and 2020, respectively.

     

  • Motus GI Holdings Inc. (MOTS) stock is plunging in the current trading session: what is behind this movement?

    Motus GI Holdings Inc. (MOTS) stock is plunging in the current trading session: what is behind this movement?

    Motus GI Holdings Inc. (MOTS) stock plunged in the current market at-11.94% to trade at $0.92, at the time of writing. MOTS stock closed at $1.05 in the last session. The MOTS stock traded at a volume of 1.36 million shares. This volume was lower than the average daily volume of 3.81 million shares for the past three months. MOTS shares for the past year have risen by 34.68%. MOTS stock has moved down in the past week by -19.23%. The stock has lost -5.41% in the past 90 days and added 10.14% in the past 180 days. Motus GI Holdings Inc. is currently valued at a market rate of $50.26 million with 40.38 million outstanding stocks.

    Motus GI Holdings Inc background

    Motus GI Holdings Inc. is a medical technological company that has its base of operations in Fort Lauderdale, Florida. The operational framework of the company is to provide cost-efficiency and enhancement in clinical outcome through its endoscopy solutions. The company focuses on the diagnosis and treatment of the diseases and conditions related to gastro intestine in the market of United States as well as Israel.

    What is Motus’s Pure-Vu?

    The leading product of MotusGi Holdings Inc. is known as the system of Pure-Vu. During a colonoscopy procedure sometimes the colon is poorly prepared and thus it requires cleaning of the debris, blood clots and blood so that the endoscopist can clearly see it. This cleaning is facilitated by Pure-Vu.

    Pure-Vu submitted by the company for 510(k) approval

    The company MotusGi Holdings announced on 6th April 2021, that it has submitted a 510-k form for its flagship product Pure-Vu. The submission is given to the Food and Drug Administration for Pure-Vu®. 510(K) is a clearance certificate granted by the Food and Drug Administration in order to test a product for premarket submission so that its claim of efficacy and safety can be verified and approved. Once this submission is approved, the Pure-Vu system can be immediately set-up for commercialization and marketing.

    How MOTS is trying to increase its operational footprint

    The MOTS stock is increasing its value for the shareholders through four value-driven operations which include new product innovation, clinical data, partnerships, and reimbursement.

    The new strategic partnerships include the most recent announcement of a study that will lead to evaluation of clinical and economic outcomes from utilization of Pure-Vu in patients that are suffering for emergent lower gastrointestinal bleeding. This will be done partnered with a leading non-profit organization.

    Pure-Vu can enter a potential market

    Pure-Vu is going to enter into a market of unmet needs related to the treatment of upper GI bleeding. The significance of this system in the market-accessibility sense is such that around 0.4 million patients have had upper GI bleeding in the year 2019. The fatality rate of this disease is also at a serious 10%.

    The requirement of Pure-Vu is going to be very impactful to remove adherent blood clots to clear vision through endoscopy in order for the physicians to have clarity in identifying the source of bleeding and treating it.